tiprankstipranks
Advertisement
Advertisement
SpinaFX Plans IDE Trial for Triojection Following FDA Breakthrough Designation
PremiumPrivate CompaniesSpinaFX Plans IDE Trial for Triojection Following FDA Breakthrough Designation
3M ago
SpinaFX Advances Breakthrough Spine Therapy With ASSR 2026 Workshop and Pivotal Trial Plans
Premium
Private Companies
SpinaFX Advances Breakthrough Spine Therapy With ASSR 2026 Workshop and Pivotal Trial Plans
3M ago
SpinaFX Showcases Minimally Invasive Spine Therapy and Pivotal Trial Plans at ASSR Workshop
Premium
Private Companies
SpinaFX Showcases Minimally Invasive Spine Therapy and Pivotal Trial Plans at ASSR Workshop
3M ago
SpinaFX Highlights Breakthrough Spine Therapy at Upcoming ASSR 2026 Meeting
PremiumPrivate CompaniesSpinaFX Highlights Breakthrough Spine Therapy at Upcoming ASSR 2026 Meeting
4M ago
SpinaFX Highlights Breakthrough Spine Therapy at Upcoming ASSR 2026 Meeting
Premium
Private Companies
SpinaFX Highlights Breakthrough Spine Therapy at Upcoming ASSR 2026 Meeting
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100